U.S. biopharma industry debates Treasury China investment rule impact
The U.S. biopharma industry is arguing over the significance of new Treasury Department restrictions on Chinese biotech investment proposed last week in Washington.
Debate shifts to rule effects
Industry players are now discussing how aggressive the proposed limitations will be. Some argue that licensing deals remain exempt from these new restrictions. This exemption is currently at the center of disagreements regarding the proposal's actual impact.
Strategic approaches under review
Earlier discussions focused on whether restrictions were necessary at all. The conversation has moved to comparing boosting domestic research versus preventing Chinese biotechs from advancing. Officials state that licensing agreements do not fall under the proposed limits.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.